1. Lipid Biomarkers in Alzheimer's Disease
- Author
-
Gérard Lizard, Mohamed Hammami, Amira Zarrouk, Mohamed El Ayeb, Thibault Moreau, Mustapha Cherkaoui-Malki, Meryam Debbabi, El Mostafa Karym, Boubker Nasser, Asmaa Badreddine, Maryem Bezine, Olivier Rouaud, Laboratoire Bio-PeroxIL. Biochimie du peroxysome, inflammation et métabolisme lipidique [Dijon] (BIO-PEROXIL), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université de Monastir - University of Monastir (UM), Université de Sousse, Laboratoire des Venins et Biomolécules Thérapeutiques - Laboratory of Venoms and Therapeutic Biomolecules (LR11IPT08), Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Centre Mémoire Ressources et Recherche [Dijon] (CMRR Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Université Hassan 1er [Settat], The work on lipid biomarkers carried out by the team ‘Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism’ EA7270 / Univ. Bourgogne Franche-Comté / INSERM is financially supported by: INSERM, Université de Bourgogne, ASSAD (Louhans, France), Department of Neurology (University Hospital, Dijon, France), Memory Center, Resources and Research of Burgundy (CMRR / University Hospital, Dijon, France), and Association pour le Développement des Sciences Neurologiques en Bourgogne (ADSNB, Dijon, France) and Association Bourguignonne pour les Applications des Sciences de l'Information en Médecine (ABASIM, Dijon, France). This work was also supported by grants from: Univ. Monastir (Monastir, Tunisia), Univ. El Manar (Tunis, Tunisia), Pasteur Institut (Tunis, Tunisia), Action Intégrée of the Comité Mixte Inter-Universitaire Franco-Marocain (CMIFM, AIMA/14/310, EGIDE) from the PHC Volubilis/Toubkal program, Ministère des Affaires Etrangères, Conseil Régional de Bourgogne, Ministère de l’enseignement et de la Recherche and Projet Sectoriel CNRST.
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Lipid Metabolism Disorder ,Amyloid ,phospholipids ,[SDV]Life Sciences [q-bio] ,Biology ,fatty acids ,lipids ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Alzheimer Disease ,Internal medicine ,medicine ,Animals ,Humans ,Dementia ,MESH: Animals ,MESH: Lipid Metabolism ,MESH: Humans ,Cholesterol ,biomarkers ,cholesterol ,Lipid metabolism ,Peroxisome ,Lipid Metabolism ,medicine.disease ,MESH: Lipids ,3. Good health ,030104 developmental biology ,Endocrinology ,Neurology ,chemistry ,Docosahexaenoic acid ,Alzheimer ,MESH: Biomarkers ,oxysterols ,lipids (amino acids, peptides, and proteins) ,Neurology (clinical) ,Alzheimer's disease ,MESH: Alzheimer Disease ,030217 neurology & neurosurgery - Abstract
Background: There are now significant evidences that lipid metabolism is affected in numerous neurodegenerative diseases including Alzheimer’s disease. These dysfunctions lead to abnormal levels of certain lipids in the brain, cerebrospinal fluid and plasma. It is consequently of interest to establish lipid profiles in neurodegenerative diseases. This approach, which can contribute to identify lipid biomarkers of Alzheimers' disease, can also permit to identify new therapeutic targets. It was therefore of interest to focus on central and peripheral biomarkers in Alzheimer's disease. Methods: A review of the literature on 148 papers was conducted. Based on this literature, the involvement of lipids (cholesterol and oxysterols, fatty acids, phospholipids) in Alzheimer's disease has been proposed. Results: Of the 148 references cited for lipid biomarkers for Alzheimer's disease, 65 refer to cholesterol and oxysterols, 35 to fatty acids and 40 to phospholipids. Among these lipids, some of them such as 24S-hydroxyckolesterol, open up new therapeutic perspectives in gene therapy, in particular. The results on the very long-chain fatty acids suggest the potential of peroxisomal dysfunctions in Alzheimer's disease. As for the phospholipids, they could constitute interesting biomarkers for detecting the disease at the prodromal stage. Conclusion: There are now several lines of evidence that lipids play fundamental roles in the pathogenesis of AD and that some of them have a prognostic and diagnosis value. This may pave the way for the identification of new therapeutic targets, new effective drugs and / or new treatments.
- Published
- 2018